US Bancorp DE Sells 2,960 Shares of Charles River Laboratories International, Inc. $CRL

US Bancorp DE reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 35.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,351 shares of the medical research company’s stock after selling 2,960 shares during the period. US Bancorp DE’s holdings in Charles River Laboratories International were worth $812,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Exchange Traded Concepts LLC grew its holdings in shares of Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after buying an additional 76 shares during the last quarter. Brooklyn Investment Group grew its stake in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after acquiring an additional 102 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Charles River Laboratories International by 6.8% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock worth $290,000 after buying an additional 123 shares in the last quarter. Finally, Empirical Finance LLC grew its stake in shares of Charles River Laboratories International by 10.2% in the 1st quarter. Empirical Finance LLC now owns 1,442 shares of the medical research company’s stock worth $217,000 after buying an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CRL shares. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price objective for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Finally, Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, October 3rd. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $181.29.

Charles River Laboratories International Trading Up 2.0%

Shares of CRL stock opened at $178.37 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The company has a 50 day moving average price of $160.84 and a 200 day moving average price of $148.29. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock has a market capitalization of $8.78 billion, a P/E ratio of -134.11, a price-to-earnings-growth ratio of 4.77 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the previous year, the firm earned $2.80 earnings per share. The firm’s quarterly revenue was up .6% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).